ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Kaliglutol®:Streuli Pharma AG
Vollst. FachinformationDDDDrucken 
Gal.Form/Ther.Gr.Zusammens.Eigensch.Pharm.kinetikInd./Anw.mögl.Dos./Anw.Anw.einschr.Unerw.Wirkungen
Interakt.Überdos.Sonstige H.Swissmedic-Nr.Stand d. Info. 
A12BA01 - Potassium ChlorideATC-DDD Version 2016. Source: WHO
A - Alimentary Tract and Metabolism
 
A12 - Mineral Supplements

This group contains mineral supplements used for treatment of mineral deficiency. All parenteral solutions of electrolytes are classified in B05B or in B05X. Magnesium carbonate used for treatment of mineral deficiency is classified in A02AA01.

A12B - Potassium
 
A12BA - Potassium

This group comprises preparations used as potassium supplements.
This group comprises also all combined potassium preparations used in the treatment of potassium deficiency conditions. Potassium citrate preparations indicated for e.g. treatment of renal tubular acidosis with calcium stones are classified here.
Small non-therapeutic amounts of potassium hydrogencarbonate are allowed at each level of plain potassium salts.
Potassium, combinations with other drugs, are classified at separate 5th levels using the corresponding 50-series.
Diuretics and potassium in combination, see C03 - Diuretics.
See also B05 - Blood substitutes and perfusion solutions.

The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.

A12BA01 - Potassium Chloride
StärkeAdm.RouteNote
 O 
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home